Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 127 for:    exosomes

Clinical Research for the Consistency Analysis of PD-L1 in Lung Cancer Tissue and Plasma Exosome Before and After Radiotherapy (RadImm02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02869685
Recruitment Status : Unknown
Verified August 2016 by Jianguo Sun, Xinqiao Hospital of Chongqing.
Recruitment status was:  Not yet recruiting
First Posted : August 17, 2016
Last Update Posted : September 1, 2016
Sponsor:
Information provided by (Responsible Party):
Jianguo Sun, Xinqiao Hospital of Chongqing

Brief Summary:
The detection of tissue PD-L1 immunohistochemistry in NSCLC has an important role in guiding for the treatment of immune detection point.Radiation therapy can enhance the effect of immunotherapy,but radiation dose and timing are waiting to be solved. At the same time,tissue detection is time-consuming and laborious, liquid biopsy can reflect the information of tumor tissue,PD-L1 mRNA in plasma exosomes (pExo) is expected to be simple, rapid, non-invasive means of detection. The project is planned to explore the consistency analysis of PD-L1 expression level detected in tissues and pExo before and after radiotherapy.We have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.PD-L1 mRNA levels in pExo detected at different time points,by using variance analysis of repeated measures design information.Probing the best timing and manner of radiotherapy division which can make PD-L1 express more,guiding clinical practice of radiotherapy combining with immunotherapy.

Condition or disease Intervention/treatment Phase
NSCLC Radiation: radiotherapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Research for the Consistency Analysis of PD-L1 in Lung Cancer Tissue and Plasma Exosome Before and After Radiotherapy
Study Start Date : October 2016
Estimated Primary Completion Date : June 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
a prospective, open,phase I clinical study
We have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
Radiation: radiotherapy



Primary Outcome Measures :
  1. The match rate of PD-L1 protein expression in tumor tissue and PD-L1 mRNA expression in pExo before radiotherapy. [ Time Frame: up to two and a half years ]
  2. The match rate of PD-L1 protein expression in tumor tissue and PD-L1 mRNA expression in pExo after radiotherapy. [ Time Frame: up to two and a half years ]
  3. The best radiotherapy-division which can make PD-L1 express more. [ Time Frame: up to two and a half years ]
  4. The best timing of radiotherapy which can make PD-L1 express more. [ Time Frame: up to two and a half years ]

Secondary Outcome Measures :
  1. Correlation between PD-L1 expression through radiation-induced and the ORR. [ Time Frame: up to two and a half years ]
  2. Correlation between PD-L1 expression through radiation-induced and the radiation pneumonitis. [ Time Frame: up to two and a half years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Pathological histology and/or cytology confirmed NSCLC;
  2. Based on AJCC Cancer Staging, IIIA, IIIB, IV lung cancer patients with NSCLC;
  3. PS 0-2;
  4. Expected survival > 3 months;
  5. Age 18~75 years old;
  6. The function of lung, liver, kidney, bone marrow was normal;
  7. The patients had not received radiotherapy for previous primary tumor and metastases;
  8. At least accept 2−4 cycles of chemotherapy,not disease progression after chemotherapy,start radiotherapy in two weeks after the last cycle of chemotherapy;
  9. Wild-type EGFR;
  10. Sensitive mutant EGFR, but refused to targeted therapy;
  11. In line with the indications of radiotherapy and accept it;
  12. Voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent.

Exclusion Criteria:

  1. Vital organs (e.g., heart, liver, kidney) have serious dysfunction;
  2. Patients with other malignancies;
  3. Patients with a history of autoimmune disease;
  4. The patients are pregnant and lactating (Women of childbearing age need to check the pregnancy test);
  5. In the activity of acute or chronic infectious diseases;
  6. Patients with a clear history of drug allergy or allergic genus;
  7. Patients with participating in other clinical trials at the same time;
  8. Other cases that researchers believe that patients should not participate in the present trial.

Layout table for additonal information
Responsible Party: Jianguo Sun, Deputy Director, Xinqiao Hospital of Chongqing
ClinicalTrials.gov Identifier: NCT02869685     History of Changes
Other Study ID Numbers: XQonc-003
First Posted: August 17, 2016    Key Record Dates
Last Update Posted: September 1, 2016
Last Verified: August 2016